Karyopharm Therapeutics(KPTI) - 2024 Q4 - Annual Results

Exhibit 99.1 Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives – Preliminary Unaudited Full Year 2024 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $113 Million, Respectively – NEWTON, Mass. – January 13, 2025 – Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 total revenue and ...